{"id":"4cmenb","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain"},{"rate":null,"effect":"Injection site erythema"},{"rate":null,"effect":"Injection site swelling"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"4CMenb contains capsular polysaccharide from meningococcal serogroup B conjugated to a carrier protein, which enhances immunogenicity and promotes both humoral and cellular immune responses. The vaccine elicits antibodies and T-cell responses that provide protection against invasive meningococcal disease caused by serogroup B strains.","oneSentence":"4CMenb is a meningococcal serogroup B conjugate vaccine that stimulates immune responses against Neisseria meningitidis serogroup B.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:25:39.822Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B"}]},"trialDetails":[{"nctId":"NCT04350138","phase":"PHASE2","title":"Safety and Efficacy Study of Meningococcal Group B Vaccine rMenB+OMV NZ (Bexsero) to Prevent Gonococcal Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-12-29","conditions":"Gonococcal Infection","enrollment":2606},{"nctId":"NCT05766904","phase":"PHASE3","title":"Efficacy Trial on Meningococcal B Vaccine for Preventing Gonorrhea Infections","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2023-05-04","conditions":"Gonorrhea, Sexually Transmitted Infection","enrollment":150},{"nctId":"NCT05294588","phase":"PHASE2","title":"Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2022-04-18","conditions":"Gonorrhea Male","enrollment":65},{"nctId":"NCT03621670","phase":"PHASE3","title":"Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-07-27","conditions":"Infections, Meningococcal","enrollment":1196},{"nctId":"NCT07395739","phase":"PHASE1","title":"A Phase I Clinical Trial to Assess the Safety and Immunogenicity of DX-104","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Yuguan Biotech Co., Ltd.（Delonix Bioworks)","startDate":"2026-02-24","conditions":"Neisseria Meningitidis Serogroup B","enrollment":30},{"nctId":"NCT06832514","phase":"PHASE4","title":"Investigating Gender and Sex Differences in Immune Responses Through Vaccination of Transgender and Cisgender Persons","status":"RECRUITING","sponsor":"University Ghent","startDate":"2025-01-31","conditions":"Meningococcal Meningitis, Serogroup B, Transgender Persons, Sex Differences in Immune Response","enrollment":250},{"nctId":"NCT06647407","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-11-05","conditions":"Meningococcal Immunization, Healthy Volunteers","enrollment":750},{"nctId":"NCT06128733","phase":"PHASE1, PHASE2","title":"Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2023-10-31","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":1215},{"nctId":"NCT07252804","phase":"PHASE4","title":"Immunogenicity and Safety of MenB Vaccine in Pediatric Patients With Autoimmune Rheumatic Diseases","status":"NOT_YET_RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2026-01-01","conditions":"Autoimmune Rheumatologic Disease","enrollment":263},{"nctId":"NCT06995430","phase":"PHASE3","title":"A Phase 3 Study to Assess the Immune Response And Safety Of Rmenb+Omv Nz In Primed Healthy Participants (10 To 20 Years Old)","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-07-07","conditions":"Meningitis","enrollment":226},{"nctId":"NCT04166656","phase":"PHASE3","title":"Research Trial Assessing the Immunogenicity and Safety of Three Meningococcal B Vaccine Strategies Among Patients With Asplenia.","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-09-15","conditions":"Splenectomy","enrollment":84},{"nctId":"NCT04825223","phase":"PHASE1","title":"Study of a Novel Multicomponent Meningococcal Group B Vaccine When Given Alone or With Other Licensed Vaccines in Adults, Adolescents, Toddlers and Infants","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2021-03-29","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":576},{"nctId":"NCT04084769","phase":"PHASE3","title":"Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine, in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine (MCV4)","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-09-03","conditions":"Meningococcal Immunisation (Healthy Volunteers)","enrollment":570},{"nctId":"NCT06446752","phase":"PHASE3","title":"BIYELA - Bexsero Immunisation in Young Women in Africa","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Washington","startDate":"2024-08-14","conditions":"Gonorrhea, Gonorrhea of Pharynx, Gonorrhea of Anus","enrollment":1100},{"nctId":"NCT04886154","phase":"PHASE1, PHASE2","title":"A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-06-14","conditions":"Infections, Meningococcal","enrollment":1440},{"nctId":"NCT05082285","phase":"PHASE2","title":"A Study on the Safety, Tolerability and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-11-29","conditions":"Infections, Meningococcal","enrollment":724},{"nctId":"NCT06033261","phase":"PHASE1, PHASE2","title":"A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2023-09-06","conditions":"Genital Herpes","enrollment":365},{"nctId":"NCT04415424","phase":"PHASE3","title":"Efficacy Study of 4CMenB (Bexsero®) to Prevent Gonorrhoea Infection in Gay and Bisexual Men","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kirby Institute","startDate":"2021-07-08","conditions":"Neisseria Gonorrheae Infection","enrollment":650},{"nctId":"NCT04318548","phase":"PHASE3","title":"Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine When Administered Concomitantly With GSK Meningococcal MenACWY Conjugate Vaccine in Healthy Subjects of 16-18 Years of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2020-08-25","conditions":"Infections, Meningococcal","enrollment":945},{"nctId":"NCT02868970","phase":"PHASE4","title":"Pharmacists as Immunizers to Improve Coverage and Provider/Recipient Satisfaction","status":"COMPLETED","sponsor":"Canadian Immunization Research Network","startDate":"2017-02-15","conditions":"Healthy","enrollment":2404},{"nctId":"NCT06025487","phase":"PHASE2","title":"Meningococcal B Vaccine in Patients with Asplenia","status":"RECRUITING","sponsor":"Medical University of Vienna","startDate":"2024-03-12","conditions":"Splenectomy; Status","enrollment":80},{"nctId":"NCT04722003","phase":"PHASE2","title":"Mucosal Immunity Against Neisseria Gonorrhoeae After 4CMenB Vaccination","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-11-01","conditions":"Gonorrhoea","enrollment":52},{"nctId":"NCT04707391","phase":"PHASE3","title":"Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-01-25","conditions":"Meningitis, Meningococcal","enrollment":1250},{"nctId":"NCT04645966","phase":"PHASE2","title":"A Clinical Trial to Assess the Safety, Tolerability and Immunogenicity of MenABCWY in Healthy Infants","status":"TERMINATED","sponsor":"Pfizer","startDate":"2020-11-26","conditions":"Meningococcal Vaccine","enrollment":326},{"nctId":"NCT04502693","phase":"PHASE3","title":"Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2020-08-14","conditions":"Infections, Meningococcal","enrollment":3657},{"nctId":"NCT06242730","phase":"","title":"Doxycycline PEP and 4CMenB as a Comprehensive Prevention Strategy in MSM and TGW at High Risk for Bacterial STIs Within the Swiss HIV Cohort Study","status":"UNKNOWN","sponsor":"University of Zurich","startDate":"2023-11-01","conditions":"Doxycycline STI PEP","enrollment":400},{"nctId":"NCT04295733","phase":"","title":"Safety, Tolerability and Immunogenicity of 4CMenB Vaccine(2 Doses) in Adults With an Immunodeficiency","status":"COMPLETED","sponsor":"Ospedale Policlinico San Martino","startDate":"2020-02-06","conditions":"Acquired Immunodeficiency","enrollment":98},{"nctId":"NCT03632720","phase":"PHASE3","title":"Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers When Administered Concomitantly With Routine Pediatric Vaccines in the United Kingdom","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-10-10","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":788},{"nctId":"NCT03493919","phase":"PHASE4","title":"A Sourcing Study to Collect Human Blood Samples From Healthy Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-03-08","conditions":"Meningitis, Meningococcal","enrollment":1021},{"nctId":"NCT04398849","phase":"","title":"Immunisation for Adolescents Against Serious Communicable Diseases (B Part of it NT)","status":"UNKNOWN","sponsor":"University of Adelaide","startDate":"2021-03-04","conditions":"Gonorrhea, Meningococcal Disease","enrollment":7100},{"nctId":"NCT03636906","phase":"PHASE1, PHASE2","title":"Respiratory Syncytial Virus (RSV) Investigational Vaccine in Infants Aged 6 and 7 Months Likely to be Unexposed to RSV","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-04-08","conditions":"Respiratory Syncytial Virus Infections","enrollment":201},{"nctId":"NCT04297436","phase":"NA","title":"Gonococcal Vaccine Study in Key Populations in Kenya","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2021-05-31","conditions":"Gonorrhea","enrollment":50},{"nctId":"NCT04239430","phase":"","title":"Propositive (Protecting Positive People From Meningococcal Infection) Follow-up Study","status":"UNKNOWN","sponsor":"St George's, University of London","startDate":"2020-11-26","conditions":"HIV/AIDS, Meningococcal Disease","enrollment":55},{"nctId":"NCT02398396","phase":"NA","title":"Investigating Meningococcal Vaccines in Adults","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2015-04","conditions":"Meningococcal Vaccines, Meningococcal Infections, Neisseria Meningitidis","enrollment":15},{"nctId":"NCT02482636","phase":"PHASE2","title":"Baby Vaccine Study (Sched3)","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2015-08","conditions":"Infectious Diseases","enrollment":189},{"nctId":"NCT04094883","phase":"PHASE4","title":"Study to Assess Gonorrhoeae Immune Responses Induced by a N. Meningitidis Vaccine","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2019-10-09","conditions":"Neisseria Gonorrhoeae Infection","enrollment":11},{"nctId":"NCT04875819","phase":"PHASE4","title":"Safety and Immunogenicity Following Meningococcal and Pneumococcal Immunization Among Adult People Living With HIV","status":"RECRUITING","sponsor":"Thomas Benfield","startDate":"2021-04-28","conditions":"Hiv, Meningococcal Infections, Pneumococcal Infections","enrollment":55},{"nctId":"NCT03125616","phase":"PHASE4","title":"Babies Born Early Antibody Response to Men B Vaccination: BEAR Men B","status":"COMPLETED","sponsor":"St George's, University of London","startDate":"2017-08-01","conditions":"Prematurity, Vaccination, Meningococcal Disease","enrollment":136},{"nctId":"NCT02640677","phase":"","title":"Safety of 4CMenB Exposure During Pregnancy","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-01-31","conditions":"Infections, Meningococcal","enrollment":2},{"nctId":"NCT02173704","phase":"PHASE3","title":"Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine Vaccines to Healthy Infants of 2 Months of Age and Older, in Taiwan.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-09-11","conditions":"Meningococcal Disease, Infections, Meningococcal","enrollment":225},{"nctId":"NCT03587207","phase":"PHASE2","title":"Study to Assess Potential Immune Interference When GlaxoSmithKline (GSK) Biologicals' MenABCWY Vaccine is Administered to Healthy Subjects Aged 10-25 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-07-09","conditions":"Meningitis, Meningococcal","enrollment":520},{"nctId":"NCT02712177","phase":"","title":"Bexsero™and Routine Infant Vaccines: Effect of Coadministration on the Safety of Immunization","status":"COMPLETED","sponsor":"CHU de Quebec-Universite Laval","startDate":"2008-08","conditions":"Meningococcal Infections","enrollment":4535},{"nctId":"NCT03089086","phase":"PHASE4","title":"South Australian Meningococcal B Vaccine Herd Immunity Study","status":"COMPLETED","sponsor":"University of Adelaide","startDate":"2017-04-01","conditions":"Meningococcal Disease","enrollment":34489},{"nctId":"NCT02212457","phase":"PHASE2","title":"Trial to Assess Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-08-21","conditions":"Infections, Meningococcal","enrollment":1063},{"nctId":"NCT03682939","phase":"PHASE4","title":"Evaluation of Safety and Immunogenicity of Meningococcal B and Meningococcal ACWY Vaccine in at Risk Population","status":"UNKNOWN","sponsor":"St George's, University of London","startDate":"2019-02-21","conditions":"Hiv, Meningitis, Meningococcal, HIV Infections","enrollment":55},{"nctId":"NCT00661713","phase":"PHASE2, PHASE3","title":"Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine Administered to Healthy Adolescents According to Different Vaccination Schedules","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2008-06","conditions":"Meningococcal Disease","enrollment":1631},{"nctId":"NCT02583412","phase":"PHASE4","title":"Pilot Study of the Immunogenicity, Reactogenicity and Tolerability of Two Schedules of a 4CmenB Vaccine in Adolescents and Young Adults","status":"COMPLETED","sponsor":"Canadian Immunization Research Network","startDate":"2015-09","conditions":"Meningococcal Serogroup B","enrollment":120},{"nctId":"NCT02080559","phase":"PHASE4","title":"Investigating the Immune Response to 4CMenB in Infants","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2014-07-21","conditions":"Meningitis","enrollment":187},{"nctId":"NCT00962624","phase":"PHASE2","title":"Study of Meningococcal B Vaccine and ACWY Conjugate Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"Prof. Elizabeth Miller","startDate":"2010-07","conditions":"Meningococcal Meningitis, Serogroup A, Meningococcal Meningitis, Serogroup B, Meningococcal Meningitis, Serogroup C","enrollment":38},{"nctId":"NCT02106390","phase":"PHASE3","title":"Safety and Immunogenicity of GlaxoSmithKline Biologicals Meningococcal Group B Vaccine When Administered Concomitantly With GlaxoSmithKline Biologicals MenACWY Conjugate Vaccine to Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-06-05","conditions":"Infections, Meningococcal","enrollment":750},{"nctId":"NCT02491463","phase":"PHASE1","title":"A Study to Assess the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' RSV Investigational Vaccine (ChAd155-RSV) (GSK3389245A) in Healthy Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-07-23","conditions":"Respiratory Synctial Virus Infections","enrollment":73},{"nctId":"NCT00297817","phase":"PHASE2","title":"Study of the Safety and Immune Response of Two Serogroup B Meningococcal Vaccines Administered to Healthy Adolescents","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2006-02","conditions":"Meningococcal Disease","enrollment":203},{"nctId":"NCT00137917","phase":"PHASE2","title":"Immunogenicity & Safety Study of a Meningococcal Serogroup B Vaccine Given in a 3 Dose Schedule to Healthy Adolescents Aged 12-18 Yrs","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2002-07","conditions":"Infections, Meningococcal","enrollment":478},{"nctId":"NCT00560313","phase":"PHASE2","title":"Safety, Tolerability and Immunogenicity of Three Doses of Novartis Meningococcal B Vaccine When Administered to Healthy At-risk Adults","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2007-07","conditions":"Meningococcal Disease","enrollment":54},{"nctId":"NCT00937521","phase":"PHASE2","title":"Safety and Immunogenicity in Dose-Ranging and Formulation-Finding Meningococcal B (MenB) Vaccine Study in 2-month-old Infants","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2009-07","conditions":"Meningococcal Meningitis, Meningococcal Infections","enrollment":1507},{"nctId":"NCT01423084","phase":"PHASE3","title":"Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years","status":"COMPLETED","sponsor":"Novartis","startDate":"2011-08","conditions":"Meningococcal Disease, Meningococcal Meningitis","enrollment":344}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":417,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Bexsero"],"phase":"marketed","status":"active","brandName":"4CMenb","genericName":"4CMenb","companyName":"CHU de Quebec-Universite Laval","companyId":"chu-de-quebec-universite-laval","modality":"Biologic","firstApprovalDate":"","aiSummary":"4CMenb is a meningococcal serogroup B conjugate vaccine that stimulates immune responses against Neisseria meningitidis serogroup B. Used for Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}